Efficacy and Safety of Biosimilar AVT05 Versus Reference Product Golimumab in Combination with Methotrexate in Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results of a Randomized, Parallel-Group, Double-Blind Study

The trial is registered at ClinicalTrials.gov (ClinicalTrials.gov identifier: NCT05842213) and the EU Clinical Trials Register (EudraCT Number: 2022-001825-63).

Authors

Steffen Leutz
Fausto Berti (ORCID: https://orcid.org/0000-0002-7684-1792)
Laxmikant Vashishta
Abid Sattar
Katarina Petrović
Masna Rai (ORCID: https://orcid.org/0000-0003-1760-6597)
Monica Luque
Kristina Zhelyazkova
Richard Bucknall

Institutions

Alvotech (Germany) (DE)
Spital Thurgau (Switzerland) (CH)

Publication Details

Journal: BioDrugs
Published: 2025-11-03
DOI: https://doi.org/10.1007/s40259-025-00748-8
Citations: 1
Primary Topic: Biosimilars and Bioanalytical Methods
Type: article
Field-Weighted Citation Impact: 0.80

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Efficacy and Safety of Biosimilar AVT05 Versus Reference Product Golimumab in Combination with Methotrexate in Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results of a Randomized, Parallel-Group, Double-Blind Study

Steffen Leutz, Fausto Berti, Laxmikant Vashishta, Abid Sattar et al.

Nov 3, 2025

1 citations

BioDrugs

Biosimilars and Bioanalytical Methods

0.80

article

Efficacy and Safety of Biosimilar AVT05 Versus Reference Product Golimumab in Combination with Methotrexate in Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results of a Randomized, Parallel-Group, Double-Blind Study

Steffen Leutz, Fausto Berti, Laxmikant Vashishta, Abid Sattar, Katarina Petrović, Masna Rai, Monica Luque, Kristina Zhelyazkova, Richard Bucknall

November 3, 2025article en

1 citations

Abstract

The trial is registered at ClinicalTrials.gov (ClinicalTrials.gov identifier: NCT05842213) and the EU Clinical Trials Register (EudraCT Number: 2022-001825-63).

BioDrugsVol. 40(1)

Alvotech (Germany) (DE), Spital Thurgau (Switzerland) (CH)

Openalex Percentile: Top 22%

Biosimilars and Bioanalytical Methods

0.80

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.